Biohaven enrolls first patient in phase 3 trial of taldefgrobep alfa in spinal muscle atrophy (sma)

New haven, conn. , july 7, 2022 /prnewswire/ -- biohaven pharmaceutical holding company ltd.
BHVN Ratings Summary
BHVN Quant Ranking